Dexmedetomidine
- Generic Name
- Dexmedetomidine
- Brand Names
- Dexdor, Igalmi, Precedex, Dexmedetomidine Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16N2
- CAS Number
- 113775-47-6
- Unique Ingredient Identifier
- 67VB76HONO
- Background
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
- Indication
Administered intravenously, dexmedetomidine is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in intensive care settings, and for the sedation of non-intubated patients prior to and/or during surgery and other procedures. It is also available as a buccally- or sublingually-administered dissolvable film...
- Associated Conditions
- Agitation, Alcohol Withdrawal Syndrome
- Associated Therapies
- -
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Ram Selvaraju, H.C. Wainwright analyst, maintains Buy rating on Bioxcel Therapeutics (BTAI) with $7.00 price target, citing SERENITY At-Home Phase 3 trial initiation for BXCL501, IGALMI's post-marketing study success, and FDA's positive review of SERENITY protocol. Canaccord Genuity also reiterates Buy rating with $7.00 target.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath